- Home
- TKLF vs MTVA Comparison
TKLF vs MTVA Comparison
Compare TKLF & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- MTVA
- Stock Information
- Founded
- TKLF 2006
- MTVA 2014
- Country
- TKLF Japan
- MTVA United States
- Employees
- TKLF N/A
- MTVA N/A
- Industry
- TKLF Other Specialty Stores
- MTVA
- Sector
- TKLF Consumer Discretionary
- MTVA
- Exchange
- TKLF Nasdaq
- MTVA NYSE
- Market Cap
- TKLF 13.3M
- MTVA 15.1M
- IPO Year
- TKLF 2022
- MTVA N/A
- Fundamental
- Price
- TKLF $3.79
- MTVA $0.69
- Analyst Decision
- TKLF
- MTVA Strong Buy
- Analyst Count
- TKLF 0
- MTVA 2
- Target Price
- TKLF N/A
- MTVA $7.50
- AVG Volume (30 Days)
- TKLF 31.3K
- MTVA 599.8K
- Earning Date
- TKLF 07-15-2025
- MTVA 05-14-2025
- Dividend Yield
- TKLF N/A
- MTVA N/A
- EPS Growth
- TKLF N/A
- MTVA N/A
- EPS
- TKLF 1.70
- MTVA N/A
- Revenue
- TKLF $219,520,631.00
- MTVA N/A
- Revenue This Year
- TKLF N/A
- MTVA N/A
- Revenue Next Year
- TKLF N/A
- MTVA N/A
- P/E Ratio
- TKLF $2.24
- MTVA N/A
- Revenue Growth
- TKLF 32.02
- MTVA N/A
- 52 Week Low
- TKLF $2.05
- MTVA $0.63
- 52 Week High
- TKLF $8.53
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- TKLF 51.77
- MTVA N/A
- Support Level
- TKLF $3.57
- MTVA N/A
- Resistance Level
- TKLF $4.00
- MTVA N/A
- Average True Range (ATR)
- TKLF 0.22
- MTVA 0.00
- MACD
- TKLF -0.03
- MTVA 0.00
- Stochastic Oscillator
- TKLF 53.97
- MTVA 0.00
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores; Online Stores and Services; and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from China followed by Japan and other overseas markets.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.